Center-Authored Papers

Filters: Author is Shamberger, Robert C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
2010
Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith BJ, Ritchey ML, Haase GM, Donaldson M, Grundy PE, Weetman R et al..  2010.  Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5.. Annals of surgery. 251(3):555-8. Abstract
2011
Lange J, Peterson SM, Takashima JR, Grigoriev Y, Ritchey ML, Shamberger RC, Beckwith BJ, Perlman E, Green DM, Breslow NE.  2011.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.. The Journal of urology. 186(2):378-86. Abstract
2012
Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, Feusner JH, Shamberger RC, Green DM, Breslow NE.  2012.  Treatments and outcomes for end-stage renal disease following Wilms tumor.. Pediatric nephrology (Berlin, Germany). Abstract
2014
Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith BJ, Perlman EJ, Shamberger RC, Peterson S et al..  2014.  Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 61(1):134-9. Abstract
Antineoplastic Combined Chemotherapy Protocols
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
April 2012
Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, Feusner JH, Shamberger RC, Green DM, Breslow NE.  2012.  Treatments and outcomes for end-stage renal disease following Wilms tumor.. Pediatric nephrology (Berlin, Germany). Abstract
Carboplatin
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Center-Authored Paper
Lange J, Peterson SM, Takashima JR, Grigoriev Y, Ritchey ML, Shamberger RC, Beckwith BJ, Perlman E, Green DM, Breslow NE.  2011.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.. The Journal of urology. 186(2):378-86. Abstract
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Green DM, Breslow NE, D'Angio GJ, Malogolowkin MH, Ritchey ML, Evans AE, Beckwith BJ, Perlman EJ, Shamberger RC, Peterson S et al..  2014.  Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 61(1):134-9. Abstract
Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith BJ, Ritchey ML, Haase GM, Donaldson M, Grundy PE, Weetman R et al..  2010.  Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5.. Annals of surgery. 251(3):555-8. Abstract
Child, Preschool
Lange J, Peterson SM, Takashima JR, Grigoriev Y, Ritchey ML, Shamberger RC, Beckwith BJ, Perlman E, Green DM, Breslow NE.  2011.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.. The Journal of urology. 186(2):378-86. Abstract
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Collaborative Data Services Core Facility
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Combined Modality Therapy
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Consortium Authored Paper
Lange J, Peterson SM, Takashima JR, Grigoriev Y, Ritchey ML, Shamberger RC, Beckwith BJ, Perlman E, Green DM, Breslow NE.  2011.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.. The Journal of urology. 186(2):378-86. Abstract
Dactinomycin
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Doxorubicin
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Drug Administration Schedule
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Etoposide
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
February 2013
Ehrlich PF, Anderson JR, Ritchey ML, Dome JS, Green DM, Grundy PE, Perlman EJ, Kalapurakal JA, Breslow NE, Shamberger RC.  2013.  Clinicopathologic Findings Predictive of Relapse in Children With Stage III Favorable-Histology Wilms Tumor.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Female
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract
Genes, Wilms Tumor
Lange J, Peterson SM, Takashima JR, Grigoriev Y, Ritchey ML, Shamberger RC, Beckwith BJ, Perlman E, Green DM, Breslow NE.  2011.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.. The Journal of urology. 186(2):378-86. Abstract
Humans
Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PRM, Grundy PE, D'Angio GJ et al..  2008.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.. Pediatric blood & cancer. 50(2):236-41. Abstract